POpPART: Optimized Management After Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension

Sponsor
University Hospital, Grenoble (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04777448
Collaborator
(none)
54
2
27

Study Details

Study Description

Brief Summary

Balloon pulmonary angioplasty (BPA) is a new method of treatment for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent CTEPH after surgery. BPA improves or even normalises hemodynamic parameters measured during a right heart catheterization. Nevertheless, the vast majority of patients retain dyspnea and impaired exercise capacity despite considerable hemodynamic improvements.

Pulmonary rehabilitation (RHB) can improve symptoms, quality of life and exercise capacity in patients with CTEPH. Unfortunately, access to RHB remains a concern in many countries. Tele-rehabilitation (tRHB) has been shown feasible and effective some cardiac or pulmonary diseases.

This randomized controlled study aims at comparing the effects of tRHB with the effects of simple advices regarding exercising in CTEPH patients with normalized or near-normalized pulmonary hemodynamics after BPA treatment.

Condition or Disease Intervention/Treatment Phase
  • Procedure: telerehabilitation
N/A

Detailed Description

Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of pulmonary embolism leading to dyspnea, effort limitation and sometimes right heart failure and death. Balloon pulmonary angioplasty (BPA) is a new method of treatment for inoperable CTEPH or persistent CTEPH after surgery. BPA restores blood flow in the treated areas and improves or even normalises hemodynamic parameters measured during a right heart catheterization. Nevertheless, the vast majority of patients retain dyspnea and impaired exercise capacity after angioplasty procedures.

Exercise training has been demonstrated to alleviate exercise dyspnea and to improve exercise capacity in many chronic cardiopulmonary conditions. Pulmonary rehabilitation (RHB) can improve symptoms, quality of life and exercise capacity in patients with pulmonary vascular disease of different etiologies including CTEPH. Furthermore, RHB does not present any particular risk for CTEPH patients with normalized or near-normalized pulmonary hemodynamics. Unfortunately, access to RHB remains a concern in many countries. Tele-rehabilitation (tRHB) has been shown feasible and effective some cardiac or pulmonary diseases. Our hypothesis is that tRHB may also be effective in CTEPH patients with normalized or near-normalized pulmonary hemodynamics after BPA treatment.

This randomized controlled study aims at comparing the effects of tRHB with the effects of simple advices regarding exercising in CTEPH patients with normalized or near-normalized pulmonary hemodynamics after BPA treatment.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
54 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Optimised Management After Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension
Anticipated Study Start Date :
Apr 1, 2021
Anticipated Primary Completion Date :
Apr 1, 2023
Anticipated Study Completion Date :
Jul 1, 2023

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control

Simple physical activity advices will be given to the 27 patients of the control arm

Experimental: telerehabilitation

Patients in the tele rehabilitation arm will perform 24 1h-telerehabilition sessions (dance, gym, cardio training, yoga, ...)

Procedure: telerehabilitation
24 sessions (less Thant 1h hour each) of tele rehabilitation. Patients can choose among several activities (gym, dance, cardio training, ...)

Outcome Measures

Primary Outcome Measures

  1. Difference of endurance time on cycloergometer [At inclusion and after 3 months]

    Expressed in seconds and calculated as follow: endurance time after 3 months - endurance time at inclusion The two tests are performed at 80% of the maximum power reached during a maximum incremental effort test (performed before inclusion)

Secondary Outcome Measures

  1. 6-minutes walking test (6MWT) [At inclusion and at Month 3]

    Distance walked in 6-min (in meters)

  2. 3-minutes chair rise test (3-CRT) [At inclusion and at Month 3]

    Number of rises during 3-CRT (n)

  3. SF-36 [At inclusion and at Month 3]

    Physical dimensions of the SF-36 questionnaire

  4. Dyspnea (NYHA scale) [At inclusion, at Month 1, Month 2 and Month 3]

    Either I, II, III or IV

  5. Telerehabilitation [Through study completion, an average of 3 months]

    Total number of sessions achieved

  6. St George Respiratory Questionnaire (SGRQ) [At inclusion and at Month 3]

    Total SGRQ score

  7. Dyspnea (mMRC score) [At inclusion, at Month 1, Month 2 and Month 3]

    Either 0, 1, 2, 3 or 4

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age > 18 years old

  • Patients who have undergone pulmonary angioplasty for CTEPH (group 4 of the international classification)

  • Patients with a mean pulmonary artery pressure <= 30 mmHg and cardiac output > 2.5 L/min/m2 at the last angioplasty session

  • Patients who had completed an incremental cardiopulmonary exercise test

  • Patients affiliated to the French social security system

  • Patients with signed informed consent

Exclusion Criteria:
  • Patients unable to complete an incremental cardiopulmonary exercise test

  • Patients unable to complete a 6-minutes walking test, 3-minutes chair raising test and a rehabilitation

  • Patient unable, for technical or any other reason, to connect via the Internet for remote monitoring and/or telerehabilitation

  • Patient for whom a refusal to participate in a rehabilitation programme is anticipated

  • Patient who has participated in a rehabilitation programme in the 6 months prior to the date of inclusion

  • Patients referred to in Articles L1121-5 to L1121-8 of the CSP (pregnant women, parturients, nursing mothers, persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care and adults subject to a legal protection measure or unable to express their consent).

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University Hospital, Grenoble

Investigators

  • Principal Investigator: Bruno Degano, MD, PhD, CHU Grenoble Alpes

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Grenoble
ClinicalTrials.gov Identifier:
NCT04777448
Other Study ID Numbers:
  • EssaiClinique_POPPART
First Posted:
Mar 2, 2021
Last Update Posted:
Mar 2, 2021
Last Verified:
Mar 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University Hospital, Grenoble
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 2, 2021